Cintas Joins The Network of Employers for Traffic Safety Board of Directors
The Network of Employers for Traffic Safety (NETS) is pleased to announce that Cintas has joined the organization's Board of Directors.
Cintas provides solutions for workwear and apparel, facilities, first aid & safety, fire protection and beyond and employs more than 46,000 employee-partners serving more than 1 million customers in the U.S. and Canada with more than 11,700 routes distributing products and services.
'NETS welcomes Cintas and its Board Representatives, Matt Presendofer, Safety & Health Manager and Chris Culpepper, Corporate Safety Trainer and Support,' said Susan Hipp, NETS' Executive Director. 'Cintas has a long-standing commitment to safety and embodies a spirit of resourcefulness, innovation, and collaboration, making them a valuable and like-minded resource for NETS. NETS' Board of Directors could not be more pleased and we look forward to collaborating with Matt and Chris on our shared mission of advancing road safety.'
NETS' Board of Directors members are comprised of public and private sector leaders with a commitment to road safety. They are senior level leaders who promote NETS' mission and represent businesses and organizations that have created a proactive safety culture by promoting traffic safety policies and awareness activities in their workplaces.
Cintas joins current board members Acertus, Chubb, Consolidated Edison, Hess Corporation, Johnson & Johnson, Lockton, State Farm Insurance, Toyota North America, UPS, and USIC. In addition, the National Highway Traffic Safety Administration (NHTSA) and the National Institute for Occupational Safety and Health (NIOSH) serve as federal liaisons to the board of directors.
About NETS
NETS, founded in 1991, is a global 501(C)3 public/private partnership dedicated to improving the safety of employees, their families, and members of the communities in which they live and work by preventing traffic crashes that occur both on and off-the-job.
NETS member companies have drivers operating in more than 130 countries representing a collective fleet of nearly half a million vehicles, traveling more than seven billion miles annually. NETS is a member of the United Nations Road Safety Collaboration, which provides guidance to the Decade of Action for Road Safety 2021-2030 global initiative. For more information on NETS, visit www.trafficsafety.org
SOURCE: The Network of Employers for Traffic Safety
Copyright Business Wire 2025.
PUB: 03/25/2025 09:35 AM/DISC: 03/25/2025 09:35 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
Ms. Cupples brings extensive global commercial leadership and rare disease product launch experience NEWTON, Mass., June 09, 2025--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Courtney Cupples as Chief Commercial Officer (CCO). Ms. Cupples brings more than 25 years of global commercial leadership and rare disease product launch experience. "We are excited to welcome Courtney to Abcuro as a key member of the leadership team as we prepare for the potential commercialization of our lead asset, ulviprubart, currently in Phase 3 clinical development for the potential treatment of inclusion body myositis (IBM), a rare and debilitating muscle disease," said Alex Martin, Chief Executive Officer. "Courtney has extensive expertise in global commercial strategy, commercial team leadership, and has worked on several successful orphan drug launches." Ms. Cupples most recently served as Chief Commercial Officer for Priovant Therapeutics, where she led commercial launch preparation for the company's oral small molecule, brepocitinib, currently in development for the potential treatment of severe autoimmune diseases. She began her career at Genzyme Corporation where she served in various commercial roles for over 11 years, driving expansion of the company's enzyme replacement therapy business in Latin America. She then spent nine years at Alexion Pharmaceuticals where she led the launch of Soliris® (eculizumab) in Latin America, served as leader of the $1 billion global franchise for the atypical hemolytic uremic syndrome (aHUS) indication for (Soliris®) and led the global metabolic disease franchise for Strensiq® (asfotase alfa) and Kanuma® (sebelipase alfa). Following Alexion, Ms. Cupples joined Biohaven Pharmaceuticals to lead commercial strategic planning for the company's clinical-stage rare disease portfolio focused primarily on neuromuscular conditions. Ms. Cupples holds a Bachelor of Arts in Sociology & Anthropology from Swarthmore College. "I am thrilled to join Abcuro's team of innovative, experienced and passionate individuals whose collective commitment to turning groundbreaking science into a potentially life-transforming treatment for people with a devastating disease like IBM is truly inspiring," said Ms. Cupples. "I look forward to partnering with this talented team as we move into this exciting next chapter together, including initial data from the MUSCLE study expected in the first half of 2026." About Ulviprubart Ulviprubart (ABC008) is a first-in-class anti-KLRG1 antibody product candidate capable of selectively depleting highly cytotoxic T cells, while sparing naïve, regulatory and central memory T cells. Ulviprubart is designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL). The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have each granted orphan drug designation to ulviprubart for the treatment of IBM. About Inclusion Body Myositis (IBM) IBM is a rare and debilitating autoimmune disease in which highly cytotoxic T cells chronically attack muscle tissue leading to progressive weakness and limb muscle atrophy. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. There are currently no available disease-modifying treatment options and no cure for IBM. Based on published epidemiology literature, it is estimated that there are more than 50,000 people with IBM across the US and Europe. About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company's lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at View source version on Contacts Matthew DeYoungInvestor Relations and MediaArgot Partnersabcuro@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Ellington Credit Declares Monthly Common Dividend
OLD GREENWICH, Conn., June 09, 2025--(BUSINESS WIRE)--Ellington Credit Company (NYSE: EARN) ("we" or the "Fund") today announced that its Board of Trustees has declared a monthly common dividend of $0.08 per share, payable on July 31, 2025 to shareholders of record as of June 30, 2025. Cautionary Statement Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical in nature and can be identified by words such as "anticipate," "estimate," "will," "should," "may," "expect," "project," "believe," "intend," "seek," "plan" and similar expressions or their negative forms, or by references to strategy, plans, or intentions. Forward-looking statements are based on our beliefs, assumptions and expectations of our future operations, business strategies, performance, financial condition, liquidity and prospects, taking into account information currently available to us. These beliefs, assumptions, and expectations are subject to numerous risks and uncertainties and can change as a result of many possible events or factors, not all of which are known to us. If a change occurs, our business, financial condition, liquidity, results of operations and strategies may vary materially from those expressed or implied in our forward-looking statements. The following factors are examples of those that could cause actual results to vary from those stated or implied by our forward-looking statements: changes in interest rates and the market value of our investments, market volatility, changes in the default rates on corporate loans, our ability to borrow to finance our assets, changes in government regulations affecting our business, a deterioration in the market for collateralized loan obligations, our ability to adapt to the new regulatory regime associated with our conversion to a closed-end fund/RIC, potential business disruption related to our conversion to a closed-end fund/RIC, ability to achieve the anticipated benefits of our conversion to a closed-end fund/RIC, the acceptance by the IRS of the proposed change to our tax year, and other changes in market conditions and economic trends, such as changes to fiscal or monetary policy, heightened inflation, increased tariffs, slower growth or recession, and currency fluctuations. Furthermore, as stated above, forward-looking statements are subject to numerous risks and uncertainties, including, among other things, those described under the heading "Risk Factors" in our Registration Statement on Form N-2, which can be accessed through the link to our SEC filings under "For Investors" on our website (at or at the SEC's website ( Other risks, uncertainties, and factors that could cause actual results to differ materially from those projected or implied may be described from time to time in reports we file with the SEC, and is not possible for us to predict or identify them all. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. This release and the information contained herein do not constitute an offer of any securities or solicitation of an offer to purchase securities. About Ellington Credit Company Ellington Credit Company (the "Fund") is a non-diversified closed-end fund that seeks to provide attractive current yields and risk-adjusted total returns by investing primarily in collateralized loan obligations ("CLOs"), with a focus on mezzanine debt and equity tranches. The Fund is externally managed and advised by an affiliate of Ellington Management Group, L.L.C., a leading fixed-income investment manager founded in 1994. The Fund benefits from Ellington's extensive experience and deep expertise in portfolio management, credit analysis, and risk management. For additional information, visit View source version on Contacts Investors:Ellington Credit CompanyInvestor Relations(203) 409-3773info@ orMedia:Amanda Shpiner/Grace CartwrightGasthalter & Ellington Credit Company(212) 257-4170Ellington@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Ellington Financial Declares Common and Preferred Dividends
OLD GREENWICH, Conn., June 09, 2025--(BUSINESS WIRE)--Ellington Financial Inc. (NYSE: EFC) ("we") today announced that its Board of Directors has declared the following: (i) a monthly dividend of $0.13 per share of common stock, payable on July 31, 2025 to common stockholders of record as of June 30, 2025; (ii) a quarterly dividend of $0.615341 per share on the Company's Series A Floating Rate Cumulative Redeemable Preferred Stock, payable on July 30, 2025 to Series A preferred stockholders of record as of June 30, 2025; (iii) a quarterly dividend of $0.390625 per share on the Company's 6.250% Series B Fixed-Rate Reset Cumulative Redeemable Preferred Stock, payable on July 30, 2025 to Series B preferred stockholders of record as of June 30, 2025; (iv) a quarterly dividend of $0.5390625 per share on the Company's 8.625% Series C Fixed-Rate Reset Cumulative Redeemable Preferred Stock, payable on July 30, 2025 to Series C preferred stockholders of record as of June 30, 2025; and (v) a quarterly dividend of $0.4375 per share on the Company's 7.00% Series D Cumulative Perpetual Redeemable Preferred Stock, payable on June 30, 2025 to Series D preferred stockholders of record as of June 20, 2025. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve numerous risks and uncertainties. Our actual results may differ from its beliefs, expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements are not historical in nature and can be identified by words such as "believe," "expect," "anticipate," "estimate," "project," "plan," "continue," "intend," "should," "would," "could," "goal," "objective," "will," "may," "seek" or similar expressions or their negative forms, or by references to strategy, plans, or intentions. Forward-looking statements are based on our beliefs, assumptions and expectations of our future operations, business strategies, performance, financial condition, liquidity and prospects, taking into account information currently available to us. These beliefs, assumptions, and expectations are subject to risks and uncertainties and can change as a result of many possible events or factors, not all of which are known to us. If a change occurs, our business, financial condition, liquidity, results of operations and strategies may vary materially from those expressed or implied in our forward-looking statements. The following factors are examples of those that could cause actual results to vary from our forward-looking statements: changes in interest rates and the market value of our investments, market volatility, changes in mortgage default rates and prepayment rates, our ability to borrow to finance our assets, changes in government regulations affecting our business, our ability to maintain our exclusion from registration under the Investment Company Act of 1940, our ability to maintain our qualification as a real estate investment trust, or "REIT," and other changes in market conditions and economic trends, such as changes to fiscal or monetary policy, heightened inflation, slower growth or recession, and currency fluctuations. Furthermore, forward-looking statements are subject to risks and uncertainties, including, among other things, those described under Item 1A of our Annual Report on Form 10-K, which can be accessed through our website at or at the SEC's website ( Other risks, uncertainties, and factors that could cause actual results to differ materially from those projected or implied may be described from time to time in reports we file with the SEC, including reports on Forms 10-Q, 10-K and 8-K. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. This release and the information contained herein do not constitute an offer of any securities or solicitation of an offer to purchase securities. About Ellington Financial Ellington Financial invests in a diverse array of financial assets, including residential and commercial mortgage loans and mortgage-backed securities, reverse mortgage loans, mortgage servicing rights and related investments, consumer loans, asset-backed securities, collateralized loan obligations, non-mortgage and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments. Ellington Financial is externally managed and advised by Ellington Financial Management LLC, an affiliate of Ellington Management Group, L.L.C. View source version on Contacts Investors:Ellington FinancialInvestor Relations(203) 409-3575info@ orMedia:Amanda Shpiner/Grace CartwrightGasthalter & Ellington Financial(212) 257-4170ellington@ Sign in to access your portfolio
